状体体积的动态与多发性硬化症中疲劳的存在和发展有关
Martina Rubin1,2,3, Paolo Preziosa1,2,3, Monica Margoni1,2,4
1Neuroimaging Research Unit, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milano, Italy.
Journal of neurology, neurosurgery, and psychiatry
|October 10, 2024
概括
状 (CP) 体积增加和扩大与多发性硬化症 (MS) 的疲劳有关. 这些变化可能反映了正在进行的中枢神经系统炎症,导致MS相关的疲劳.
科学领域:
- 神经免疫学 神经免疫学
- 神经成像是一种神经成像.
- 多发性硬化症的发病因子
背景情况:
- 免疫过程有助于多发性硬化症 (MS) 的疲劳.
- 冠状动脉 (CP) 影响中枢神经系统 (CNS) 免疫平衡,其体积变化可能与MS疲劳有关.
- 这项研究研究了CP体积变化与MS疲劳动力学之间的联系.
研究的目的:
- 探索状 (CP) 体积的变化与多发性硬化症 (MS) 中疲劳的发展或存在之间的关联.
- 了解CP体积变化的作用在中枢神经系统免疫活动和MS相关疲劳的背景下.
主要方法:
- 85名多发性硬化患者和68名健康对照 (HC) 接受了脑部MRI和临床评估,时间均为1.4年.
- 使用先进的成像技术量化正常化的大脑体积,区域灰质 (GM) 体积和胆脉 (CP) 体积.
- 使用线性混合模型分析了CP体积的纵向变化,将发现与疲劳状态相关联 (修改疲劳影响量表).
主要成果:
- 在基线时,MS患者与HC相比,CP体积更高. 疲劳性多发性硬化症患者 (f-MS) 的CP体积数量比非疲劳性多发性硬化症患者 (nf-MS) 的CP体积高.
- 随着时间的推移,与HC相比,MS患者的脑部和深度转基因缩率更高.
- 与HC相比,所有MS组的CP体积显著增加,与那些在随访期间出现疲劳的人 (f-FU-MS) 相比,与那些没有疲劳的人 (nf-FU-MS) 相比,在随访期间出现疲劳的人群中观察到更大的扩大.
结论:
- 较大的胆管 (CP) 体积和较大的CP扩大与多发性硬化症 (MS) 疲劳的存在和发展有关.
- 这些发现表明中枢神经系统内的动态炎症过程,突出显示了免疫学对MS相关疲劳的贡献.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Increased Intracranial Pressure ll: Pathophysiology
Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins with...
01:22Cerebral Edema ll: Pathophysiology
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
01:21Cytotoxic Edema: Pathophysiology
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...